# Judith Li

> Judith Li is a Series A investor at Lilly Asia Ventures backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures)
- Location: Hong Kong, Hong Kong
- Total investments: 11
- Last investment: Jan 2026
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/judithjli/

Judith Li is a Series A investor at Lilly Asia Ventures in Hong Kong focused on Biotechnology and Health Care. Judith J. Li is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith holds board appointments at a variety of LAV’s portfolio companies, including Crown Biosciences (6554:TT),Just Biotherapeutics, Veritas Genetics, and Nextcure. Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong, splitting her time between Hong Kong, Shanghai, and the Bay Area.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 45% |
| Health Care | 4 | 36% |
| Therapeutics | 3 | 27% |
| Biopharma | 2 | 18% |
| Medical | 1 | 9% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 36% |
| Seed | 2 | 18% |
| Series B | 2 | 18% |
| Funding Round | 2 | 18% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 36% |
| China | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Precede Biosciences | Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M | Series B | Jan 12, 2026 |  |
| Precede Biosciences | Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. |  |  | Oct 05, 2023 |  |
| Precede Biosciences | Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $57M | Series A | Oct 05, 2023 |  |
| Rgenta Therapeutics | Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $52M | Series A | Nov 29, 2022 |  |
| Rgenta Therapeutics | Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $18M | Seed | May 25, 2021 |  |
| SciNeuro | SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases. | $100M | Series A | Dec 08, 2020 |  |
| Tmunity Therapeutics | Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $35M | Series A | Apr 19, 2018 |  |
| Tmunity Therapeutics | Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $100M | Series A | Jan 23, 2018 |  |
| Gritstone bio | Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS. | $93M | Series B | Sep 07, 2017 |  |
| Tmunity Therapeutics | Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $10M |  | Jan 12, 2016 |  |

10 of 11 investments shown.

## Co-investors
- [Parker Institute for Cancer Immunotherapy](https://shizune.co/investors/profile/parker-institute-for-cancer-immunotherapy) — VC Fund, 3 deals together
- [Penn Medicine Co-Investment Program](https://shizune.co/investors/profile/penn-medicine-co-investment-fund) — VC Fund, 3 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Be The Match BioTherapies](https://shizune.co/investors/profile/be-the-match-biotherapies) — VC Fund, 2 deals together
- [Binney Street Capital](https://shizune.co/investors/profile/binney-street-capital) — VC Fund, 2 deals together

## About Lilly Asia Ventures

VC Fund · Shanghai, China

Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities inChina, although they will consider investment opportunities elsewhere in east and south Asia.

4 contacts available at Lilly Asia Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Jiaxin Li | partner | https://shizune.co/investors/profile/jiaxin-li-815c |
| Judith Li | Partner | https://shizune.co/investors/profile/judith-li |
| Stella Shi | Venture Partner | https://shizune.co/investors/profile/stella-shi-yibin |
| Yi Shi | Managing Director & Founder | https://shizune.co/investors/profile/yi-shi-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Judith Li invest in?

Judith Li invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Judith Li last invest?

The most recent investment recorded for Judith Li closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co